Biotech, Food & Drug

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Feb
9
2024
Congressional Delegation Comments on Pending Petition Regarding “Free Range” and “Pasture-Raised” Claims Keller and Heckman LLP
Feb
9
2024
This Week in 340B: January 31 – February 7, 2024 McDermott Will & Emery
Feb
8
2024
Rules of Evidence Require Weighing Relevance of Evidence Against Potential Prejudice McDermott Will & Emery
Feb
8
2024
Fraud May Not Always Unravel All–What Does the Contract Say? K&L Gates
Feb
7
2024
Opioid Treatment Programs: SAMHSA Makes Permanent Regulatory Flexibilities Foley & Lardner LLP
Feb
7
2024
FDA Announces Update to Fruit Pouch Contamination Investigation Keller and Heckman LLP
Feb
7
2024
NJ Approves Cannabis Regulatory Amendment with Major Impacts on Class 5 Retail License Holders Epstein Becker & Green, P.C.
Feb
7
2024
Regulatory Compliance Is Now More Accessible for the Cannabis and Hemp Insurance Market Wilson Elser Moskowitz Edelman & Dicker LLP
Feb
6
2024
New California Bills Would Require Naloxone in the Workplace to Respond to Drug Overdoses Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Feb
6
2024
5 Trends to Watch: 2024 Class Actions Greenberg Traurig, LLP
Feb
6
2024
New SAMHSA Rule Expands Access to Medications for the Treatment of Opioid Use Disorder Polsinelli PC
Feb
6
2024
China Solicits Comments on Food Labeling Standard Keller and Heckman LLP
Feb
6
2024
Florida Governor Supports Lab-Grown (Cultivated) Meat Ban Keller and Heckman LLP
Feb
6
2024
Unpacking Averages: Device Manufacturers Should Use the Newly Released Demographic Data in MDRs to Ensure Their Devices Are Not Disproportionately Hurting Minorities Epstein Becker & Green, P.C.
Feb
6
2024
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2024
Cannabis Rescheduling: HHS Findings and Legal Implications Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2024
Don’t Assume Nonalcoholic Beverage Ingredients Are OK for Alcoholic Beverages McDermott Will & Emery
Feb
5
2024
Healthcare Preview for the Week of: February 5, 2024 [PODCAST] McDermott Will & Emery
Feb
5
2024
EPA Formally Reinstates All Chlorpyrifos Tolerances but Signals It Will Revoke Most of Them in the Future Beveridge & Diamond PC
Feb
5
2024
Court Finds Red Cross Has Antitrust Immunity, Rejecting Broad Interpretation of the Sherman Act McDermott Will & Emery
Feb
5
2024
2023 Retail Industry Year in Review Hunton Andrews Kurth
Feb
2
2024
McDermottPlus Check-Up: February 2, 2024 McDermott Will & Emery
Feb
1
2024
EuropaBio Publishes Biomanufacturing Global Series Reports on the United States, India, and Japan Bergeson & Campbell, P.C.
Feb
1
2024
Illinois to Ban Certain Food Additives, Following California, New York, and New Jersey Keller and Heckman LLP
Feb
1
2024
Bringing A New Healthy Food Ingredient to Market: Understanding the Regulatory Pathways Foley & Lardner LLP
Jan
31
2024
FDA Revises Draft HARPC Guidance Keller and Heckman LLP
Jan
31
2024
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial Sheppard, Mullin, Richter & Hampton LLP
Jan
30
2024
Blue Diamond “Smokehouse” Almonds Challenged Keller and Heckman LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins